Multiple sclerosis and pregnancy. Impact of multiple sclerosis disease-modifying therapy on the health of newborns

Background. Due to the high prevalence of multiple sclerosis (MS) among women of reproductive age, special attention is paid to the management of pregnancy in them. The problem concerning the health of infants born to mothers with MS receiving disease-modifying therapy has not yet been addressed. It is necessary to identify the timing of cessation of drugs changing the course of MS, as well as to find the possibility of mitigating exacerbations during pregnancy using corticosteroid therapy.

Objective: to analyze the effects of causal therapy for MS on the health of newborns.

Materials and methods. This study included 154 women with MS residing in Moscow region and receiving disease-modifying therapy. We evaluated the course of pregnancy, delivery, and the condition of infants born to these mothers.

Results and conclusions. Our findings are consistent with the earlier published data in the general cohort of pregnant women and allowed us to conclude that the presence of MS and history of immunomodulatory therapy do not significantly affect the outcome of pregnancy. The incidence and severity of disorders in infants born to MS mothers did not significantly differ from those in the general population. Prolongation of therapy with drugs that change the course of MS up to pregnancy is most appropriate, since it stabilizes the condition of women in the perinatal period, without causing significant harm to the health of newborns. Immunosuppressive therapy increases the risk of various disorders in infants (such as multiple malformations, low birth weight, prematurity). If a woman develops an exacerbation of MS during pregnancy, it is possible to prescribe a short course of pulse therapy with methylprednisolone.

1. Babenko L.A., Malkova N.A. Multiple sclerosis: pregnancy and drugs that change the course of multiple sclerosis. Proceedings of 10th Russian Congress of Neurologists with international participation. Nizhny Novgorod, 2012. Pp. 200–201. (In Russ.).

2. Boyko A.N., Bykova O.V., Sivertseva S.A. Multiple sclerosis in children and adolescents: clinical manifestations, diagnosis, and treatment. Moscow: Medical Information Agency LLC, 2016. 408 p. (In Russ.).

3. Korobko D.S., Malkova N.A., Kudryavtseva E.A., Filippenko M.L. Genetic analysis of family cases of multiple sclerosis. Proceedings of 10th Russian Congress of Neurologists with international participation. Nizhny Novgorod, 2012. P. 223. (In Russ.).

4. Kotov S.V., Yakushina T.I. Multiple sclerosis and pregnancy. Characteristics of pregnancy, delivery, and postpartum period in women with multiple sclerosis. Results of patients’ follow-up in Moscow region. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2015;12(23):720–4. (In Russ.).

5. Popova E.V., Korobko D.S., Bulatova E.V. et al. Retrospective analysis evaluating the effect of pregnancy on the course of multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(8):18–22. (In Russ.). DOI: 10.17116/jnevro20151158218-21.

6. Shmidt T.E., Yakhno N.N. Multiple sclerosis. Guideline for doctors. 2nd edn. Moscow: MEDpress-inform, 2010. Pp. 22, 23, 233–237. (In Russ.).

7. Yakushina T.I., Kotov S.V., Yakushin M.A. Analysis of pregnancy course, delivery, and postpartum period in women with multiple sclerosis. Almanakh klinicheskoy meditsyny = Almanac of Clinical Medicine 2015;(39):82–8. (In Russ.).

8. Coyle P.K. Multiple sclerosis and pregnancy prescriptions. Expert Opinion Drug Saf 2014;13(12):1565–8.

9. Coyle P.K. Multiple sclerosis in pregnancy. Continuum(NY) 2014;20(1):42–59. DOI: 10.1212/01.CON.0000443836.18131.c9.

10. Coyle P.K., Johnson K.P., Pardo L., Stark Y. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003;60(Suppl 1):60.

11. FDA Pregnancy Categories. Available at: http://www.drugs.com/pregnancy-categories.html.

12. Ghezzi A., Annovazzi P., Portaccio E. et al. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol 2013;9(7):891–5. DOI: 10.1586/1744666x.2013.811046.

13. Martinelli Boneschi F. Genetics of multiple sclerosis: current and emerging candidates. Annual conference “Multiple sclerosis: improving patient outcomes through scientific and clinical advances”. Dubai, 2014.

14. Proschmann U., Thomas K., Thiel S. et al. Natalizumab during pregnancy and lactation. Mult Scler 2018;24(12):1627–34. DOI: 10.1177/1352458517728813.

15. Sandberg-Wollheim M., Alteri E., Moraga M.S., Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta1a therapy. Mult Scler 2011;17:423–30. DOI: 10.1177/1352458510394610.

16. Singer B.A. Initiating oral fingolimod treatment in patient with multiple sclerosis. Ther Adv Neurol Disord 2013;6(4). DOI: 10.1177/1756285613491520.

17. Van der Kor M.L., Pearce M.S., Dahlgren L. et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol 2011;70:41–50. DOI: 10.1002/ana.22483.

18. Voldsgaard A., Sorensen S. Immunophatogenesis and therapy MS. MS Forum. Danish MS Center, 2014.